Bosutinib in chronic myeloid leukemia: patient selection and perspectives
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2018/04/01
-
Journal
-
Indian UGC (journal)
-
Citations1
-
Susanne Isfort
-
Tim H Brümmendorf
Cite
Isfort, Susanne, and Tim H Brümmendorf. “Bosutinib in Chronic Myeloid Leukemia: Patient Selection and Perspectives”. Journal of Blood Medicine, vol. Volume 9, 2018, pp. 43-50, https://doi.org/10.2147/jbm.s129821.
Isfort, S., & Brümmendorf, T. H. (2018). Bosutinib in chronic myeloid leukemia: patient selection and perspectives. Journal of Blood Medicine, Volume 9, 43-50. https://doi.org/10.2147/jbm.s129821
Isfort, Susanne, and Tim H Brümmendorf. “Bosutinib in Chronic Myeloid Leukemia: Patient Selection and Perspectives”. Journal of Blood Medicine Volume 9 (2018): 43-50. https://doi.org/10.2147/jbm.s129821.
Isfort S, Brümmendorf TH. Bosutinib in chronic myeloid leukemia: patient selection and perspectives. Journal of Blood Medicine. 2018;Volume 9:43-50.
Journal Category
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the blood and blood-forming organs
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemia | Hematological Oncology |
| 1 | 2022 |
Citations Analysis
The category
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 1
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemia and was published in 2022. The most recent citation comes from a 2022 study titled Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemia. This article reached its peak citation in 2022, with 1 citations. It has been cited in 1 different journals. Among related journals, the Hematological Oncology cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.